Thursday, June 25, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

PARP Inhibition in the Management of Common Cancers

Register Today for This CNE (NCPD) Virtual Event — 1.5 Credit Hours Available

Live Webinar

Join Us on Thursday, June 25
5:00 PM – 6:30 PM ET

Complimentary Registration
A link to the event will be provided after registration.


Emmanuel S Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair in
Cancer Development
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, Texas

Michael J Pishvaian, MD, PhD
Associate Professor
Department of Gastrointestinal Medical Oncology
Co-Director for Clinical Research
Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Module 1: Ovarian Cancer
  • Module 2: Breast Cancer
  • Module 3: Prostate Cancer
  • Module 4: Pancreatic Cancer
A detailed agenda will be made available in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Comprehend how DNA damage repair pathway abnormalities can be exploited via PARP inhibi­tion to elicit therapeutic benefit for patients with various neoplasms, including ovarian cancer, breast cancer, pancreatic adenocarcinoma and prostate cancer.
  • Understand the correlation between BRCA1/2 mutations and the development of hereditary cancers, and counsel patients with these genetic abnormalities regarding their long-term outlook and therapeu­tic options.
  • Assess available and emerging clinical trial data with and FDA-approved indications for the various PARP inhibitors used for ovarian cancer, and develop strategies to identify patients for whom PARP inhibition might be appropriate.
  • Recognize the FDA-endorsed indications for the commercially available PARP inhibitors in the man­agement of metastatic breast cancer, and discern how these agents can be optimally employed in nonresearch patient care.
  • Advise individuals with metastatic pancreatic adenocarcinoma found to harbor a germline BRCA mutation about recently presented clinical trial findings documenting the efficacy of PARP inhibitor maintenance therapy after the completion of first-line platinum-based chemotherapy.
  • Describe the rationale for testing patients with metastatic prostate cancer for BRCA1/2 or other related mutations, and advise individuals found to harbor these genetic abnormalities about emerging Phase III data doc­umenting the efficacy of PARP inhibition for their disease.
  • Assess the pharmacologic, pharmacodynamic and pharmacokinetic similarities and differences among the commercially available and investigational PARP inhibitors to better understand the activity and toxicities associated with these agents.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.